Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

High pCR rate in HPV+ HNSCC with nivolumab/SBRT

Publish date:: April 30, 2019

Key clinical point: Checkpoint inhibition plus SBRT appears effective and safe in HPV-positive HNSCC.

Major finding: Nine of 10 patients had a pathologic complete response.

Study details: Dose-finding phase 1/1b study of 10 male patients with head and neck squamous cell carcinoma.

Disclosures: Providence Cancer Center sponsored the study. Dr. Leidner reported having no relevant disclosures. Dr. Chung reported research funding from Lilly Oncology, and advisory board honoraria from BMS, CUE, and Ignyta.

Citation:

Leidner RS et al. AACR 2019, Abstract CT182.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in Head & Neck/Thyroid Cancers

Immunotherapy could fill unmet need in leptomeningeal metastases,

New cancer drugs may have saved more than 1.2 million Americans,

‘Tour de force’ study reveals therapeutic targets in 38% of cancer patients,

Survey quantifies COVID-19’s impact on oncology,

VTE, sepsis risk increased among COVID-19 patients with cancer,